Carine Punt DVM, ERT
Carine Punt DVM, ERT is CEO of BunyaVax BV since February 2020.
Carine gained >10 years of experience in the field of R&D drug development and biotech. After a few years of veterinary academics, she started at Teva Pharmaceuticals in 2008, focusing on the R&D development of complex generics. Since early 2014 she joined the ambitious and fast growing company ProQR Therapeutics to serve as a senior scientist in toxicology, in the mission to develop novel medicines for patients in need. As a project officer at BunyaVax from October 2019, she connected her veterinary background and human drug development experiences to support the development of vaccines against emerging bunyavirus related diseases of animals and humans. From February 2020 onwards she is appointed as CEO of BunyaVax as well and will thereby contribute to the strategic management and success of the company. Carine studied Veterinary Medicine at Utrecht University and is an European Registered Toxicologist (ERT) since 2019.